RNS Number : 0775K
Kromek Group PLC
19 December 2022

19 December 2022

Kromek Group plc
("Kromek" or the "Group")

Kromek enters further agreement with Smiths Detection

Significant expansion of agreement to include distribution of Kromek's radiation detection solutions in the Middle East and certain markets in Asia and Australasia

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has entered into a distribution agreement with Smiths Detection, a global leader in threat detection and security screening technologies.

Under the terms of the agreement, Smiths Detection will market and distribute the Group's wearable radiation detection and identification solutions in the Middle East and certain key markets in Asia and Australasia. This expands the Group's existing agreement, as announced on 7 July 2022, with Smiths Detection Inc. for distribution in North and South American markets. To date, the Group has delivered over 1,000 detectors under this partnership.

Arnab Basu, CEO of Kromek Group, said: *"We are pleased to be expanding our agreement with Smiths Detection to include the distribution and marketing of our solutions to the Middle East and parts of Asia and Australasia. This underscores the strength of our relationship and is a great endorsement of our products. With security forces globally requiring increasingly sophisticated solutions to guard against the threats of nuclear terrorism and the illicit movement of materials, the demand for our high-performance nuclear security products continues to grow."*

Michael Lea, Global Director Defence of Smiths Detection, added "*Smiths Detection are delighted to have entered into an agreement with Kromek to distribute their world-class products. We believe that they will meet the requirements of many customers across many different markets and will add a new dimension to the range of products available from Smiths Detection."*

ENDS

For further information, please contact:

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Paul Farquhar, CFO

finnCap Ltd (Nominated Adviser and Broker)
Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance — +44 (0)20 7220 0500
Tim Redfern/Charlotte Sutcliffe - ECM

Gracechurch Group (Financial PR)
Harry Chathli, Claire Norbury — +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has

manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

Further information is available at www.kromek.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRKVLFFLLLXFBF